Pharmaceutial firm Dr Reddy's Laboratories is expected to report a profit after tax of Rs 425 crore in the third quarter of FY12, a massive growth of 55.5% as compared to Rs 273 crore in a year ago quarter.

Pharma Q3: New launches, generic drug demand to aid growth

Pharmaceutical companies are expected to report healthy 15-25% year-on-year revenue growth in the third quarter, helped by new launches especially in the US and strong demand for generic drugs.

Pharma stocks results preview for Q3FY12: KRChoksey

KRChoksey has come with its December quarterly earning estimates for Pharma sector. According to the research firm, Q3FY12 is expected to be a strong quarter in terms of top-line growth mainly due to improved performance in the Indian pharmaceutical market, launch of limited competitive products in the US market & rupee depreciation.

Pharmaceutical results preview for Q3FY12: Emkay

Emkay Global Financial Services has come with its December quarterly earning estimates for pharmaceutical sector. According to the research firm the sector is expected to report a growth of 18% YoY (5% QoQ) in revenues partly driven by Rupee depreciation which is likely to be 4-5% of the overall growth.

Q2 report card: Pharma sector posts encouraging numbers

After a sluggish first quarter, pharma universe reported some encouraging numbers in the second quarter. This is with some support from stable growth in certain geographies but inflationary pressures taking a test on the other hand report CNBC-TV18's Archana Shukla.

Business from Russia, US markets add to Dr Reddy's coffers

G V Prasad, VC & CEO, Dr Reddy's Laboratories tells CNBC-TV18 that North America, Russia and the Pharmaceuticals Services and Active Ingredients (PSAI) segment led to the stupendous growth in the business.

DRL Q2 PAT seen down 6% to Rs 270 cr YoY

Dr Reddy's Labs (DRL) is expected to report a profit after tax of Rs 270 crore for the second quarter of FY12, a fall of 6% as compared to Rs 286.8 crore in the corresponding quarter of last fiscal.

Dr Reddys Sept qtr PAT seen at Rs 241 cr: KR Choksey

KR Choksey has come out with its earning estimates on Pharma sector for the quarter ended September 2011. According to the research firm, Dr. Reddys September quarter net sales are expected to go up by 7% at Rs 2008 crore, year-on-year, (YoY) basis.

Dr Reddys Sept qtr PAT seen up at Rs 295cr: Angel

Angel Broking has come out with its earning estimates on pharma sector for the quarter ended September 2011. According to the research firm, Dr Reddys Lab September quarter net sales are expected to go up by 7.6% at Rs 2,013 crore, year-on-year, (YoY) basis.

Product launch, US sales to aid growth in H2FY12: DRL

In an interview with CNBC-TV18, GV Prasad, vice-chairman & CEO of DRL spoke about the company's quarterly performance and future plans.

Dr Reddy's Labs expects stronger growth from US market

Reacting on the numbers in the press conference, company's vice chairman and CEO GV Prasad said that it was a good quarter in terms of growth; the company grew by 18%, reports CNBC-TV18’s Ekta Batra.

Dr Reddy's Labs Q1 PAT seen up 34% to Rs 281 cr

Dr Reddy's Labs is expected to report a 34% rise in its first quarter FY12 profit after tax to Rs 281 crore against Rs 209.6 crore in the year ago period, as per IFRS.

Apr-June qtr: Pharma cos to see healthy sales, sick margins

Pharmaceutical sector has been in the pink of health this year with most stocks outperforming the broader market since the beginning of April. However, there could be some suffering ahead.

Dr Reddys Jun qtr PAT seen at Rs 300cr: KRChoksey

KRChoksey has come out with its earning estimates on pharma sector for the quarter ended June 2011. According to the research firm, Dr Reddys June quarter sales are expected to go up by 19% at Rs 2000 crore, year-on-year, (YoY) basis.

Dr Reddys Labs Jun qtr PAT seen up 13% at Rs 238 cr

PINC Research has come out with its earning estimates on pharma sector for the quarter ended June 2011. According to the research firm, Dr Reddys Laboratories' June quarter net revenues are expected to go up by 9.4% at Rs 1840.8 crore, year-on-year, (YoY) basis.

To improve market share, position in Germany: Dr Reddy's

GV Prasad, Vice Chairman and CEO, Dr Reddys Laboratories in an interview with CNBC-TV18 spoke about the quarterly numbers of the company and the road ahead.

Dr Reddy’s Labs Mar qtr PAT seen up at Rs 204.3 cr: MOST

Motilal Oswal has come out with its earning estimates on Pharmaceuticals sector for the quarter ended March 2011. According to the research firm, Dr Reddy’s Labs March quarter sales are expected to go up by 9.5% at Rs 1798.4 crore, year-on-year, (YoY) basis.

Dr Reddys March qtr PAT seen at Rs 277cr: KRChoksey

KRChoksey has come out with its earning estimates on pharma sector for the quarter ended March 2011. According to the research firm, Dr Reddys Laboratories March quarter sales are expected to go up by 22% at Rs 1,997 crore, year-on-year, (YoY) basis.

Unsure of how biz will shape up in German mkt: Dr Reddy's

Speaking to CNBC-TV18 on the quarter gone by, GV Prasad, Vice Chairman & CEO, Dr Reddy Laboratories said operating expenses have increased due to one-time litigation costs.

Dr Reddy's Labs Q3 PAT likely at Rs 301 cr

Dr Reddy's Labs (DRL) is set to announce its results for the quarter ended December 2010. According to CNBC-TV18 estimates, its profit after tax is expected to be at Rs 301 crore as against loss of Rs 521.7 crore on year-on-year basis, as per International Financial Reporting Standards (IFRS).

Dr Reddys Dec qtr PAT seen up at Rs 259.5cr: Angel

Angel Broking has come out with its earning estimates on the pharmaceutical sector for the quarter ended December 2010. According to the research firm, Dr Reddys Laboratories December quarter net sales are expected to go up by 10.8% to Rs 1,917 crore, Year-on-Year, (Y-o-Y) basis.

Dr Reddy Dec qtr PAT seen up 62.4% at Rs 387.9cr: Emkay

Emkay Global Financial Services has come out with its earning estimates on pharma sector for the quarter ended December 2010. According to the research firm, Dr Reddy December quarter sales are expected to go up by 20.3% to Rs 2081.2 crore, Year-on-Year, (Y-o-Y) basis.

Dr Reddys Dec qtr PAT seen up 19% at Rs 285cr: KRChoksey

KRChoksey has come out with its earning estimates on pharma sector for the quarter ended December 2010. According to the research firm, Dr. Reddys December quarter sales are expected to go up by 11% to Rs 2050 crore, Year-on-Year, (Y-o-Y) basis